At a glance
ClinicalIndex Comparison Record- ✓Stable medical condition for at least 26 weeks after cerebral infarction
- ✓Age 20-80 years at time of consent
- ✓Infarct-related foci confirmed on imaging (CT or MRI)
- ✓No cardiogenic embolic sources (mitral stenosis, prosthetic valve, endocarditis, recent MI, ventricular aneurysm, endocardial thrombosis, mitral valve prolapse in <45 years without other cause, atrial fibrillation, sick sinus syndrome, idiopathic cardiomyopathy, patent foramen ovale)
- ✕Hemorrhage or bleeding tendency (hemophilia, capillary fragility, intracranial hemorrhage, GI/urinary/other hemorrhage, hemoptysis, vitreous hemorrhage)
- ✕Pregnancy or nursing
- ✕Ischemic heart failure
- ✕Peptic ulcer disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin
In Brief
A Phase 4 clinical trial evaluating Cilostazol and Aspirin for Cerebral Infarction. Completed, enrolled 2,800 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the efficacy of cilostazol in preventing recurrence of cerebral infarction and the safety of long-term administration of the drug (100 mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral embolism) in a multi-center, double-blind, parallel-group comparison with aspirin (81 mg, once daily).
Study Details
Timeline
Interventions
oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years